Trials / Completed
CompletedNCT04827680
Clinical Evaluation of the Safety and Performance of FRF for the Treatment and Reduction of Acne Scarring
Clinical Evaluation of the Safety and Performance of Fractional Radiofrequency for the Treatment and Reduction of Acne Scarring
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Venus Concept · Industry
- Sex
- All
- Age
- 22 Years
- Healthy volunteers
- Accepted
Summary
Prospective, single centre, evaluator-blind study of the safety and performance of fractional radiofrequency (RF) for the treatment and reduction of acne scarring. The study will evaluate the progress of 20 subjects requesting treatment of acne scarring. The study will involve three treatments on both sides of the face with 3-5 week intervals between each treatment. Subjects will be followed at 6 and 12 weeks after their last treatment. Analysis will be performed on all subjects who receive at least one treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Venus Viva MD | The Venus Viva™ MD fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids, and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. |
Timeline
- Start date
- 2021-05-01
- Primary completion
- 2022-06-13
- Completion
- 2022-06-13
- First posted
- 2021-04-01
- Last updated
- 2023-10-04
- Results posted
- 2023-10-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04827680. Inclusion in this directory is not an endorsement.